{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T22:38:33Z","timestamp":1742942313708,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":46,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781493933853"},{"type":"electronic","value":"9781493933877"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-3387-7_25","type":"book-chapter","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T11:08:16Z","timestamp":1460632096000},"page":"445-469","source":"Crossref","is-referenced-by-count":7,"title":["Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine"],"prefix":"10.1007","author":[{"given":"Luke R.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"key":"25_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","author":"M Pizza","year":"2000","unstructured":"Pizza M, Scarlato V, Masignani V et al (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816\u20131820","journal-title":"Science"},{"issue":"22","key":"25_CR2","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","volume":"24","author":"MP Girard","year":"2006","unstructured":"Girard MP, Preziosi MP, Aguado MT et al (2006) A review of vaccine research and development: meningococcal disease. Vaccine 24(22):4692\u20134700","journal-title":"Vaccine"},{"key":"25_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4161\/hv.7.2.13717","volume":"7","author":"R Gasparini","year":"2011","unstructured":"Gasparini R, Panatto D (2011) Meningococcal glycoconjugate vaccines. Hum Vaccin 7:170\u2013182","journal-title":"Hum Vaccin"},{"unstructured":"Cohn AC, MacNeil JR, Clark TA et al (2013) Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports\/Centers for Disease Control 62 (Rr-2):1\u201328","key":"25_CR4"},{"key":"25_CR5","first-page":"38","volume-title":"Surveillance of invasive bacterial diseases in Europe, 2011","author":"R Whittaker","year":"2013","unstructured":"Whittaker R (2013) Invasive meningococcal disease (IMD). In: Whittaker R, Bacci S (eds) Surveillance of invasive bacterial diseases in Europe, 2011. ECDC, Stockholm, pp 38\u201352"},{"unstructured":"MacNeil J, Cohn A (2011) Meningococcal disease. In: Roush SW, Baldy LM (eds) Manual for the surveillance of vaccine-preventable diseases, 5th edn. Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA, p. 1\u201311","key":"25_CR6"},{"unstructured":"Centers for Disease Control and Prevention (CDC) (1998) Outbreaks of group B meningococcal disease\u2014Florida, 1995 and 1997. MMWR Morb Mortal Wkly Rep 47(39):833\u2013837","key":"25_CR7"},{"issue":"1","key":"25_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1478-7954-11-17","volume":"11","author":"RZ Jafri","year":"2013","unstructured":"Jafri RZ, Ali A, Messonnier NE et al (2013) Global epidemiology of invasive meningococcal disease. Popul Health Metr 11(1):17","journal-title":"Popul Health Metr"},{"key":"25_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","volume":"13","author":"J Boslego","year":"1995","unstructured":"Boslego J, Garcia J, Cruz C et al (1995) Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13:821\u2013829","journal-title":"Vaccine"},{"issue":"12 Suppl","key":"25_CR10","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1097\/01.inf.0000147645.53942.00","volume":"23","author":"J O\u2019Hallahan","year":"2004","unstructured":"O\u2019Hallahan J, Lennon D, Oster P (2004) The strategy to control New Zealand\u2019s epidemic of group B meningococcal disease. Pediatr Infect Dis J 23(12 Suppl):S293\u2013S298","journal-title":"Pediatr Infect Dis J"},{"key":"25_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","author":"G Bjune","year":"1991","unstructured":"Bjune G, Hoiby EA, Gronnesby JK et al (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093\u20131096","journal-title":"Lancet"},{"key":"25_CR12","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","volume":"340","author":"JC Moraes de","year":"1992","unstructured":"de Moraes JC, Perkins BA, Camargo MC et al (1992) Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340:1074\u20131078","journal-title":"Lancet"},{"key":"25_CR13","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/IAI.62.10.4419-4424.1994","volume":"62","author":"LG Milagres","year":"1994","unstructured":"Milagres LG, Ramos SR, Sacchi CT et al (1994) Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 62:4419\u20134424","journal-title":"Infect Immun"},{"key":"25_CR14","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","volume":"281","author":"JW Tappero","year":"1999","unstructured":"Tappero JW, Lagos R, Ballesteros AM et al (1999) Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520\u20131527","journal-title":"JAMA"},{"key":"25_CR15","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","volume":"72","author":"LD Fletcher","year":"2004","unstructured":"Fletcher LD, Bernfield L, Barniak V et al (2004) Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72:2088\u20132100","journal-title":"Infect Immun"},{"issue":"37","key":"25_CR16","first-page":"822","volume":"63","author":"S Tomczyk","year":"2014","unstructured":"Tomczyk S, Bennett NM, Stoecker C et al (2014) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >\/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 63(37):822\u2013825","journal-title":"MMWR Morb Mortal Wkly Rep"},{"unstructured":"Briere EC, Rubin L, Moro PL et al (2014) Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports\/Centers for Disease Control 63(Rr-01):1\u201314","key":"25_CR17"},{"key":"25_CR18","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1084\/jem.129.6.1385","volume":"129","author":"EC Gotschlich","year":"1969","unstructured":"Gotschlich EC, Goldschneider I, Artenstein MS (1969) Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 129:1385\u20131395","journal-title":"J Exp Med"},{"key":"25_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM197002192820803","volume":"282","author":"MS Artenstein","year":"1970","unstructured":"Artenstein MS, Gold R, Zimmerly JG et al (1970) Prevention of meningococcal disease by group C polysaccharide vaccine. NEJM 282:417\u2013420","journal-title":"NEJM"},{"issue":"Suppl 1","key":"25_CR20","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","volume":"20","author":"E Miller","year":"2001","unstructured":"Miller E, Salisbury D, Ramsay M (2001) Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl 1):S58\u2013S67","journal-title":"Vaccine"},{"issue":"6","key":"25_CR21","first-page":"645","volume":"55","author":"MH Wahdan","year":"1977","unstructured":"Wahdan MH, Sallam SA, Hassan MN et al (1977) A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull World Health Organ 55(6):645\u2013651","journal-title":"Bull World Health Organ"},{"key":"25_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","volume":"28","author":"LA Jackson","year":"2009","unstructured":"Jackson LA, Jacobson RM, Reisinger KS et al (2009) A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 28:86\u201391","journal-title":"Pediatr Infect Dis J"},{"key":"25_CR23","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1016\/j.ijid.2010.03.017","volume":"14","author":"D Stamboulian","year":"2010","unstructured":"Stamboulian D, Lopardo G, Lopez P et al (2010) Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis 14:e868\u2013e875","journal-title":"Int J Infect Dis"},{"key":"25_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1086\/317646","volume":"183","author":"P Richmond","year":"2001","unstructured":"Richmond P, Borrow R, Goldblatt D et al (2001) Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 183:160\u2013163","journal-title":"J Infect Dis"},{"key":"25_CR25","first-page":"279","volume":"45","author":"R Gold","year":"1971","unstructured":"Gold R, Artenstein MS (1971) Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ 45:279\u2013282","journal-title":"Bull World Health Organ"},{"unstructured":"Pasteur S (2013) Menactra\u00ae (Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Package Insert (v03)","key":"25_CR26"},{"key":"25_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","volume":"383","author":"DM Daugla","year":"2014","unstructured":"Daugla DM, Gami JP, Gamougam K et al (2014) Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 383:40\u201347","journal-title":"Lancet"},{"key":"25_CR28","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","author":"R Borrow","year":"2005","unstructured":"Borrow R, Balmer P, Miller E (2005) Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine 23:2222\u20132227","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"25_CR29","doi-asserted-by":"publisher","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","volume":"27","author":"CE Frasch","year":"2009","unstructured":"Frasch CE, Borrow R, Donnelly J (2009) Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27(Suppl 2):B112\u2013B116","journal-title":"Vaccine"},{"key":"25_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","volume":"2","author":"J Finne","year":"1983","unstructured":"Finne J, Leinonen M, Makela PH (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2:355\u2013357","journal-title":"Lancet"},{"key":"25_CR31","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","volume":"22","author":"J Bruge","year":"2004","unstructured":"Bruge J, Bouveret-Le Cam N, Danve B et al (2004) Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22:1087\u20131096","journal-title":"Vaccine"},{"key":"25_CR32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S1473-3099(09)70132-X","volume":"9","author":"H Lo","year":"2009","unstructured":"Lo H, Tang CM, Exley RM (2009) Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 9:418\u2013427","journal-title":"Lancet Infect Dis"},{"key":"25_CR33","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1128\/JB.187.9.3273-3276.2005","volume":"187","author":"YH Sun","year":"2005","unstructured":"Sun YH, Exley R, Li Y et al (2005) Identification and characterization of genes required for competence in Neisseria meningitidis. J Bacteriol 187:3273\u20133276","journal-title":"J Bacteriol"},{"key":"25_CR34","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1128\/IAI.59.9.2963-2971.1991","volume":"59","author":"P Ley van der","year":"1991","unstructured":"van der Ley P, Heckels JE, Virji M et al (1991) Topology of outer membrane porins in pathogenic Neisseria spp. Infect Immun 59:2963\u20132971","journal-title":"Infect Immun"},{"key":"25_CR35","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","volume":"29","author":"X Wang","year":"2011","unstructured":"Wang X, Cohn A, Comanducci M et al (2011) Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 29:4739\u20134744","journal-title":"Vaccine"},{"key":"25_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1086\/600141","volume":"200","author":"E Murphy","year":"2009","unstructured":"Murphy E, Andrew L, Lee KL et al (2009) Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200:379\u2013389","journal-title":"J Infect Dis"},{"key":"25_CR37","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","volume":"28","author":"HQ Jiang","year":"2010","unstructured":"Jiang HQ, Hoiseth SK, Harris SL et al (2010) Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086\u20136093","journal-title":"Vaccine"},{"key":"25_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/1471-2105-11-595","volume":"11","author":"KA Jolley","year":"2010","unstructured":"Jolley KA, Maiden MC (2010) BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 11:595","journal-title":"BMC Bioinformatics"},{"key":"25_CR39","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1086\/424464","volume":"190","author":"DJ Litt","year":"2004","unstructured":"Litt DJ, Savino S, Beddek A et al (2004) Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 190:1488\u20131497","journal-title":"J Infect Dis"},{"key":"25_CR40","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1128\/CVI.00252-07","volume":"15","author":"G Norheim","year":"2008","unstructured":"Norheim G, Aseffa A, Yassin MA et al (2008) Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci. Clin Vaccine Immunol 15:863\u2013871","journal-title":"Clin Vaccine Immunol"},{"key":"25_CR41","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","volume":"24","author":"R Borrow","year":"2006","unstructured":"Borrow R, Carlone GM, Rosenstein N et al (2006) Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24:5093\u20135107","journal-title":"Vaccine"},{"key":"25_CR42","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I The role of humoral antibodies. J Exp Med 129:1307\u20131326","journal-title":"J Exp Med"},{"key":"25_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1006\/biol.2000.0253","volume":"28","author":"L Jodar","year":"2000","unstructured":"Jodar L, Cartwright K, Feavers IM (2000) Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 28:193\u2013197","journal-title":"Biologicals"},{"key":"25_CR44","first-page":"289","volume":"66","author":"R Borrow","year":"2001","unstructured":"Borrow R, Carlone GM (2001) Serogroup B and C serum bactericidal assays. Methods Mol Med 66:289\u2013304","journal-title":"Methods Mol Med"},{"key":"25_CR45","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","volume":"12","author":"PC Richmond","year":"2012","unstructured":"Richmond PC, Marshall HS, Nissen MD et al (2012) Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12:597\u2013607","journal-title":"Lancet Infect Dis"},{"unstructured":"Food and Drug Administration (FDA) (2014) Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Available http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm091977.pdf. Accessed 23 Mar 2015","key":"25_CR46"}],"container-title":["Methods in Molecular Biology","Vaccine Design"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-3387-7_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T20:40:05Z","timestamp":1655498405000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-3387-7_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493933853","9781493933877"],"references-count":46,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-3387-7_25","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2016]]}}}